Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients. Issue 21 (13th October 2022)

• Record Type: Journal Article
• Authors: Peterlin, Pierre; Debord, Camille; Eveillard, Marion; Garnier, Alice; Le Bourgeois, Amandine; Guillaume, Thierry; Jullien, Maxime; Béné, Marie C.; Chevallier, Patrice
• Is Part Of: Journal of cellular and molecular medicine. Volume 26:Issue 21(2022)
• Page Start: 5486
• Page End: 5492
• Publication Date: 2022-10-13
• Subjects: ALL -- AML -- diagnosis -- MDSC -- monocytes -- survivals; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17576
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Myeloid Derived Suppressive Cells (MDSC) are capable to suppress innate and adaptive immune responses, thus favouring solid cancer progression. However, little is known about the role of MDSC in acute myeloid leukaemia (AML). In this monocentric prospective study, 73 adult AML patients, eligible for first‐line intensive chemotherapy, were included with the aim to study the influence on long‐term outcomes of peripheral blood (PB) levels of monocytic (M) MDSC (M‐MDSC) assessed by flow cytometry. A percentage of peripheral M‐MDSC higher than 0.55% of leukocytes at diagnosis and a decrease of M‐MDSC% after induction came out both as independent negative prognostic factors for leukaemia‐free and overall survival.